ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Decitabine

Also written as “decitabine”, “decitabine (5-aza-2'deoxycytidine)” and “IV Decitabine”.

Its studies are mostly in Myelodysplastic Syndromes · Leukemia, Myeloid, Acute · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Lymphoma, T-Cell, Peripheral · Leukemia, Myeloid, led by 9 companies.

Drug pageDecitabine: every studyMany companies study it; this page follows only the 28 they lead. All 277 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 5, 200928 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisaiits history only90 open or runningphase 4since Nov 5, 2009Nov 28, 2005none ahead
Otsukaits history only82 open or runningphase 3since Aug 8, 2002Jul 19, 2002none ahead
EpiDestinyits history only30 open or runningphase 1since Jan 31, 2019Jan 31, 2019none ahead
Johnson & Johnsonits history only30 open or runningphase 2since Aug 29, 2008Aug 29, 2008none ahead
AbbVieits history only10 open or runningphase 3since May 3, 2019May 3, 2019none ahead
Dong Wha Pharmaceuticalits history only10 open or runningphase 1since Sep 8, 2017Sep 8, 2017none ahead
Imunopharm Technologyits history only10 open or runningphase 1since May 14, 2018May 14, 2018none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 4since Dec 9, 2013Dec 9, 2013none ahead
Treebough Therapies11 open or runningphase 1since May 20, 2025May 20, 2025Dec 30, 2026phase 1 · NCT07006025

Also a collaborator on its studies: dsm-firmenich.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Treebough Therapies only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2025First study: phase 1 study in MDSFirst studyNCT07006025 · 20 planned · United States

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in MDSNCT07006025

TargetBeta

“DNA (cytosine-5)-methyltransferase 3A inhibitor; DNA (cytosine-5)-methyltransferase 1 inhibitor; DNA inhibitor”ChEMBL 37, by rule

Studies

The one study Treebough Therapies leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07006025MDS · United States1RecruitingDec 30, 202620

How it is read

Names in the registry

  • “Decitabine”, 14 entries
  • “decitabine”, 8 entries
  • “decitabine (5-aza-2'deoxycytidine)”, 4 entries
  • “IV Decitabine”, 1 entry
  • “Decitabine + Cedazuridine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.